Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient
Section snippets
Funding
This work was supported in part by Plan Nacional de I + D + I and Fondo Europeo de Desarrollo Regional-FEDER [RD16/0025/0040] and Fundación Progreso y Salud, Junta de Andalucia [PI-0550-2017].
Declaration of competing interest
The authors declare no conflict of interest.
Acknowledgment
We acknowledge Nutraceutical Translations for English language editing of this manuscript.
References (19)
- et al.
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
Lancet HIV
(2018) - et al.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Lancet
(2017) - et al.
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Lancet HIV
(2018) - et al.
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Lancet
(2017) - et al.
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Lancet HIV
(2019) - et al.
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Lancet HIV
(2019) - Andrea-Garnier, E., Marcellin, AG., Reliquet, V., et al. Unpublished results. Bictegravir Virology Failure with...
- et al.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I
J. Antimicrob. Chemother.
(2019) - et al.
DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites
Biotechnology
(2010)
Cited by (17)
HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report
2022, Journal of Global Antimicrobial ResistanceCitation Excerpt :We speculate that immune competence (i.e. higher CD4+ T-cell counts) can accelerate the disappearance of integrase resistance mutations. The average rate of decline of integrase mutations (–641 [IC95 = 312–971] RNA copies/day) over two periods of non-adherence to treatment (months 11–15 and 16–24) was comparable or lower to those reported for R263K in two separate clinical cases with BIC and DTG (∼320 and ∼3,000 RNA copies/day, respectively) [9,10]. The current recommendation to perform resistance genotyping within four weeks of virological non-suppression may not be sufficient in the context of typical low-level viremia during failure with DTG.
Structural Biology of HIV Integrase Strand Transfer Inhibitors
2020, Trends in Pharmacological SciencesCitation Excerpt :Another INSTI, cabotegravir (CAB), was approved in March 2020 in Canada as a two-drug regimen [13]. Many reported cases of viral resistance variants (VRVs; see Glossary) lowering susceptibility to clinically used INSTIs generate the need to design new molecules that could potentially translate into therapies [14–17]. To facilitate design of improved compounds, it is important to understand INSTI binding at the atomic level and the structural basis of resistance causing mechanisms.
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure
2020, International Journal of Antimicrobial AgentsEvaluation of Dolutegravir- and Bictegravir-Based Antiretroviral Regimen Utilization in Patients who Cannot Take Medications by Mouth
2023, Open Forum Infectious Diseases